Vor Biopharma Inc. (VOR)
$4.49
+0.22 (+5.15%)
Rating:
Recommendation:
-
| Symbol | VOR |
|---|---|
| Price | $4.49 |
| Beta | 0.000 |
| Volume Avg. | 0.10M |
| Market Cap | 168.817M |
| Shares () | - |
| 52 Week Range | 4.01-23.535 |
| 1y Target Est | - |
| DCF Unlevered | VOR DCF -> | |
|---|---|---|
| DCF Levered | VOR LDCF -> | |
| ROE | -26.70% | Sell |
| ROA | -25.47% | Sell |
| Operating Margin | - | |
| Debt / Equity | 20.48% | Neutral |
| P/E | - | |
| P/B | 0.86 | Buy |
Latest VOR news
About
Download (Excel)Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.